According to a randomized study run and reported by William D.Figg, PharmD, head of the Molecular Pharmacology Section of the Centerfor Cancer Research at the National Cancer Institute, in Bethesda, MD. And published online January 23, 2009 in the Journal of Urology (Vol. 181, pp.1104-13), Thalidomide may be effective for the treatment of men who [...]
I compiled a list of trials that are activily recruiting men with hormone refractory prostate cancer (HRPC) who have also failed chemotherapy (taxotere). Being at this point in the disease process is by far the scariest time. We face the reality that there are no more approved treatments available to control the cancer. Clinical trials [...]
OncoGenex Pharmaceuticals, Inc. (OGXI) announced that it's experimental product, OGX-011, also known as custirsen sodium, received fast track designation from the U.S. Food & Drug Administration (FDA) for the treatment of progressive metastatic prostate cancer in combination with first-line docetaxel treatment (chemotherapy). OGXI had previously received this same designation for second-line docetaxel treatment with OGX-011 [...]
A post-surgery increase of PSA (usually three increases) is the definition for a prostate cancer recurrence. The best response after these increases is to radiate the prostate bed in hopes for stopping any stray cancer cells that had escaped prior to surgery. Using salvage radiation is the only remaining treatment modality that might allow a [...]
Stories abound about men who undergo prostate cancer surgery only to have the surgery halted when their doctor sees that the cancer has left the gland. The stories go that the doctor stops the surgery leaving the gland and any other visible tumors in place just as they found them. Current statistics indicate that one [...]